Atherosclerosis is promoted by a combination of hypercholesterolemia and vascular inflammation. The function of Angiopoietin (Ang)-2, a key regulator of angiogenesis, in the maintenance of large vessels is unknown. A single systemic administration of Ang-2 adenovirus (AdAng-2) to apoE ؊/؊ mice fed a Western diet significantly reduced atherosclerotic lesion size (Ϸ40%) and oxidized LDL and macrophage content of the plaques. These beneficial effects were abolished by the inhibition of nitric oxide synthase (NOS). In endothelial cells, endothelial NOS activation per se inhibited LDL oxidation and Ang-2 stimulated NO release in a Tie2-dependent manner to decrease LDL oxidation. These findings demonstrate a novel atheroprotective role for Ang-2 when endothelial cell function is compromised and suggest that growth factors, which stimulate NO release without inducing inflammation, could offer atheroprotection.
Atherosclerosis is promoted by a combination of hypercholesterolemia and vascular inflammation. The function of Angiopoietin (Ang)-2, a key regulator of angiogenesis, in the maintenance of large vessels is unknown. A single systemic administration of Ang-2 adenovirus (AdAng-2)
to apoE ؊/؊ mice fed a Western diet significantly reduced atherosclerotic lesion size (Ϸ40%) and oxidized LDL and macrophage content of the plaques. These beneficial effects were abolished by the inhibition of nitric oxide synthase (NOS). In endothelial cells, endothelial NOS activation per se inhibited LDL oxidation and Ang-2 stimulated NO release in a Tie2-dependent manner to decrease LDL oxidation. These findings demonstrate a novel atheroprotective role for Ang-2 when endothelial cell function is compromised and suggest that growth factors, which stimulate NO release without inducing inflammation, could offer atheroprotection.
T he endothelium plays a vital role in the prevention of atherosclerosis, yet the molecular mechanisms that confer atheroprotection are poorly understood. 1 Angiopoietin (Ang)-2, a context-dependent agonist/antagonist for the Tie2 receptor, promotes vascular regression or facilitates vascular endothelial growth factor (VEGF)-driven angiogenesis. 2 Despite the extensive studies of Ang-2 in the microvasculature, its role in atherosclerosis is unknown. Ang-2 in high concentrations induces robust phosphorylation of Tie2 3 and prevents endothelial cell apoptosis 4 through activation of the prosur-vival Akt pathway, which can phosphorylate endothelial nitric oxide synthase (eNOS). 4, 5 Stressed endothelial cells express high levels of Ang-2, which acts as an autocrine Tie2 agonist to bolster Akt activity. 6 As loss of eNOS activity is an established contributor to endothelial dysfunction 7 and endothelium-derived NO plays a vital role in the prevention of atherosclerosis, 8 we explored whether Ang-2 could suppress atherosclerosis by stimulating NO release in apoE Ϫ/Ϫ mice. In this report, we show that overexpression of Ang-2 reduces lesion size, macrophage accumulation, and oxidized LDL content of plaques in atherosclerosis-prone apoE Ϫ/Ϫ mice. The protective effect of Ang-2 was abolished by NOS inhibition. Our investigation demonstrates a novel function for Ang-2 as an atheroprotective mediator that inhibits atherosclerosis through the activation of eNOS to reduce LDL oxidation.
Materials and Methods
The expanded Materials and Methods section in the online data supplement (available at http://circres.ahajournals.org) provides a description of the apoE Ϫ/Ϫ mouse model of atherosclerosis; adenoviruses; immunohistochemical, NO, and LDL oxidation methods.
Results and Discussion

Ang-2 Suppresses Atherosclerosis in apoE-Null Mice
After 3 weeks on a Western diet, 8-week-old apoE Ϫ/Ϫ mice received a single systemic administration of Ang-2 adenovirus (AdAng-2) (1.0ϫ10 10 pfu) or control adenovirus (AdEV) and euthanized 4 weeks later. All mice developed atherosclerotic lesions along the proximal aortic wall and at the valve cusps. Circulating levels of Ang-2 were detected only in the AdAng-2-treated group (meanϮSD 12.8Ϯ5.6 g/mL; Figure  I in the online data supplement), and there were no significant differences in the body weight or plasma lipid levels between the 2 groups (online Table I ). These findings suggest that the beneficial effect of Ang-2 was not attributable to suppression of appetite. AdAng-2-treated mice showed a highly significant reduction in atherosclerotic plaque lesion size compared with control mice receiving AdEV (0.269Ϯ0.04 mm 2 versus 0.437Ϯ0.05 mm 2 ; nϭ10/group; PϽ0.01; Figure 1A ). Lesion size in a separate group of uninfected animals (0.547Ϯ0.05 mm 2 ; nϭ3) was similar to AdEV-treated mice, indicating that adenoviral infection per se did not increase atherosclerosis. Histological analysis revealed a decrease in CD11b-positive macrophages/monocytes in the plaque ( Staining for CD31 showed that the aortic endothelium remains intact in the AdAng-2-treated mice. This is in marked contrast to the effect of Ang-2 promoting endothelial cell detachment reported in a 3D culture model. 10 It is possible that acute effects of Ang-2 may be deleterious, but long-term treatment may be protective. Indeed, prolonged exposure of endothelial cells to Ang-2 induces robust phosphorylation of Tie2, 3 a key prosurvival signal. 6
Ang-2 Induces NO Release From Endothelial Cells
Stimulation of human umbilical vein endothelial cells (HUVECs) with Ang-2 resulted in a concentration-dependent release of NO (Figure 2A ), which was inhibited by Tie2neutralizing antibodies and a Tie2-blocking peptide ( Figure  2B ), demonstrating this effect is Tie2-dependent. Although VEGF and Ang1 can induce NO release, 11 both can recruit inflammatory cells. 12, 13 In addition, VEGF increased plaque formation in double-deficient apoE/apoB100 mice, 14 and Ang-1 failed to protect against the development of rat cardiac allograft arteriosclerosis. 15 This paradox may be explained by the fact that unlike VEGF and Ang-1, Ang-2 has little effect on monocyte migration (online Figure II) . This ability of Ang-2 to stimulate NO release without promoting inflammatory cell recruitment gives it the characteristics of an atheroprotective factor.
Ang-2 Inhibits Endothelial-Mediated LDL Oxidation
Oxidized LDL reduces endothelial function 16 ; however, it is unknown whether NO per se can inhibit LDL oxidation in a cellular context. Therefore, we assessed NO production and LDL oxidation in porcine aortic endothelial cells (PAECs) expressing constitutively active eNOS S1177D (PAEC/ eNOS S1177D ) or control cells (PAEC/pcDNA) using thiobarbituric acid-reactive substances (TBARS) assay. PAEC/ eNOS S1177D produced significantly more NO (Online Figure  III , A) and reduced LDL oxidation compared with control cells (online Figure III, B ; PϽ0.01), an effect that was prevented by NOS inhibition indicating that NO inhibits cellular LDL oxidation.
The observed reduction in tissue LDL oxidation in Ang-2-treated animals prompted us to examine whether Ang-2 could suppress LDL oxidation by endothelial cells in vitro. In the absence of cells, native LDL oxidation was low (16.9Ϯ4.8 nmol TBARS/mg) whereas in the presence of HUVECs, LDL oxidation increased significantly (49.5Ϯ2.75 nmol TBARS/mg; Figure 2C ). Ang-2 dramatically inhibited LDL oxidation in HUVECs, as demonstrated by a 57% reduction in the formation of TBARS (23.5Ϯ4.7 nmol TBARS/mg; PϽ0.01, nϭ4; Figure 2C ), which was partially abolished by N G -nitro-L-arginine methyl ester (L-NAME). The relative electrophoretic mobility of modified LDL was used to confirm these findings ( Figure 2D) . In contrast to Ang-2, Ang-1 had no effect on LDL oxidation (Online Figure IV) . These results demonstrate that the antiathero- NNA) . B, HUVECs were pretreated with either Tie2-neutralizing (anti-Tie2; 5 g/mL) or Tie1-neutralizing (anti-Tie2; 5 g/mL) antibodies or Tie2blocking peptide (Tie2 peptide; 0.5 mmol/L) before incubation with Ang-2 (400 ng/mL) for 1 hour, and NO release was quantified. Results are meanϮSEM of 3 independent experiments (nϭ9). C and D, HUVECs were incubated in serum-free medium containing 100 g/mL LDL, 500 ng/mL Ang-2, and/or 100 mol/L L-NAME for 16 hours. Oxidative modification of LDL was assessed using: TBARS assay (data represent meanϮSEM; *PϽ0.01 vs control, #PϽ0.05 vs HUVECϩAng-2 without L-NAME) (C) and the relative electrophoretic mobility of LDL (D). genic property of Ang-2 may, in part, be attributable to its ability to inhibit LDL oxidation via an NO-dependent mechanism.
Ang-2-Mediated Atheroprotection is NO-Dependent
To investigate if the protective effect of Ang-2 in apoE Ϫ/Ϫ mice requires NO, L-NAME was administered in the drinking water 1 day after adenoviral injection. In the absence of L-NAME, AdAng-2-treated mice demonstrated a significant reduction in lesion area compared with AdEV-treatment (0.141Ϯ0.01 mm 2 versus 0.222Ϯ0.03 mm 2 ; nϭ8 to 10/ group; PϽ0.01; Figure 3A ) as before ( Figure 1 ). Inhibition of NOS had no significant effect on lesion size in AdEV-treated mice but abrogated the beneficial effects of Ang-2 ( Figure  3B ). Furthermore, AdAng-2 significantly decreased MOMA-2-positive macrophages in the lesions, an effect that was also inhibited by L-NAME ( Figure 3A and 3C ). Although lesion size was only quantified histologically without supporting en face staining, these results demonstrate that the effects of Ang-2 on lesion size were reproducible demonstrating the utility of this method for quantification of these early stage lesions.
Taken together, this study demonstrates that NO per se suppresses LDL oxidation and Ang-2 inhibits atherosclerotic lesion development, in part, by reducing LDL oxidation and macrophage accumulation via endothelial NOS activation. These results are consistent with the context and concentrationdependent nature of Ang-2 3, 6 and indicate that Ang-2 may offer atheroprotection in a hypercholesterolemic environment when endothelial cell function is compromised. It will be important to establish whether the protective effects of the transient high circulating levels of Ang-2 observed in early atherosclerotic lesions persist and can be translated into long-term benefit. Figure 3 . Ang-2-mediated reduction in atherosclerotic plaque formation requires NO. One day after administration of adenovirus, apoE Ϫ/Ϫ mice were treated with L-NAME. A, Representative images of plaques stained for neutral lipids (oil red O) and macrophage (MOMA-2) content. Quantification of mean plaque (B) and MOMA-2-positive areas (C) show that the atheroprotective effect of AdAng-2 is abolished following L-NAME treatment. Data are the mean areasϮSEM. *PϽ0.01 vs AdEV without L-NAME; §PϽ0.05, #PϽ0.01 vs AdAng-2 without L-NAME.
